title: Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?
abstract: One third of patients with metastatic renal cell carcinoma (RCC) suffer from bone metastases. Skeletal involvement in RCC is associated with the occurrence of skeletal-related events, and may negatively impact on the outcome of patients treated with systemic therapies. In patients with RCC and bone metastases, therapies that inhibit osteoclasts, as bisphosphonates and denosumab, are used as adjunct to systemic targeted therapies to prevent skeletal-related events. Data suggest that they may also improve the outcome of systemic targeted therapies. Herein we review the preclinical and clinical data on their use, as well as remaining open questions.
authors.affiliation: Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tchernichovsky 59, 44281, Kfar-Saba, Israel, danielkeizman@gmail.com.
authors.forename: Daniel
authors.initials: D
authors.lastname: Keizman
authors.forename: Maya
authors.initials: M
authors.lastname: Ish-Shalom
authors.forename: Natalie
authors.initials: N
authors.lastname: Maimon
authors.forename: Maya
authors.initials: M
authors.lastname: Gottfried
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001859:Bone Neoplasms / Q000401:mortality / Q000517:prevention & control* / Q000556:secondary*; D001862:Bone Resorption / Q000188:drug therapy; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000517:prevention & control* / Q000556:secondary*; D000069448:Denosumab; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D058990:Molecular Targeted Therapy; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D000069448:Denosumab
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: N Engl J Med. 2004 Apr 15;350(16):1655-64
references.pmid: 15084698
references.citation: N Engl J Med. 1996 Sep 19;335(12):865-75
references.pmid: 8778606
references.citation: Med Oncol. 2010 Sep;27(3):1023-6
references.pmid: 19830602
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Oct;110(4):463-9
references.pmid: 20692189
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: J Pathol. 2009 Aug;218(4):530-9
references.pmid: 19455604
references.citation: Acta Oncol. 2009;48(1):9-17
references.pmid: 18752081
references.citation: Scand J Urol Nephrol. 2009;43(2):98-103
references.pmid: 19101859
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: Oncology. 2009;76(3):209-11
references.pmid: 19212145
references.citation: Ann Oncol. 2011 Feb;22(2):295-300
references.pmid: 20657034
references.citation: Cancer Treat Rev. 2012 Jun;38(4):284-91
references.pmid: 21802857
references.citation: Semin Oncol. 2010 Jun;37 Suppl 1:S38-44
references.pmid: 20682371
references.citation: Lancet. 2011 Mar 5;377(9768):813-22
references.pmid: 21353695
references.citation: J Urol. 2006 Nov;176(5):2255-61
references.pmid: 17070308
references.citation: Semin Ultrasound CT MR. 1997 Apr;18(2):91-9
references.pmid: 9163828
references.citation: Bone. 2011 Jan;48(1):160-6
references.pmid: 20854942
references.citation: Ann Oncol. 2009 Mar;20(3):600-1
references.pmid: 19188135
references.citation: Int J Urol. 2008 Jun;15(6):546-7
references.pmid: 18489646
references.citation: Intern Med J. 2008 Aug;38(8):635-7
references.pmid: 18284458
references.citation: Int J Oncol. 2001 Aug;19(2):379-82
references.pmid: 11445855
references.citation: Urol Clin North Am. 2003 Nov;30(4):843-52
references.pmid: 14680319
references.citation: Bone. 2009 Jan;44(1):173-5
references.pmid: 18849018
references.citation: Ann Oncol. 2011 Apr;22(4):794-800
references.pmid: 20937648
references.citation: Asia Pac J Clin Oncol. 2010 Mar;6(1):5-18
references.pmid: 20398033
references.citation: World J Urol. 2005 Jul;23(3):202-12
references.pmid: 15812574
references.citation: Oncologist. 2008 Dec;13(12):1314; author reply 1315
references.pmid: 19088325
references.citation: Anticancer Res. 2008 Mar-Apr;28(2A):933-41
references.pmid: 18507039
references.citation: J Cancer Res Clin Oncol. 2010 Mar;136(3):371-8
references.pmid: 19711099
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1125-32
references.pmid: 21343556
references.citation: Ann Oncol. 2012 May;23(5):1341-1347
references.pmid: 21986094
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Cancer. 2004 Jun 15;100(12):2613-21
references.pmid: 15197804
references.citation: Eur J Cancer. 2012 Nov;48(16):3123-5
references.pmid: 22682018
references.citation: Eur J Cancer. 2012 May;48(7):1031-7
references.pmid: 22409947
references.citation: Int J Cancer. 2012 Feb 1;130(3):677-84
references.pmid: 21387300
references.citation: Clin Exp Metastasis. 2011 Apr;28(4):405-11
references.pmid: 21365325
references.citation: J Clin Oncol. 2003 Aug 15;21(16):3150-7
references.pmid: 12915606
references.citation: Cancer. 2003 Sep 1;98(5):962-9
references.pmid: 12942563
references.citation: Int J Clin Oncol. 2013 Oct;18(5):877-83
references.pmid: 22965827
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381